Merck's experimental HIV prevention pill has been projected to cost less than $5 a year, according to recent research published by STAT.
Experts are urging Merck to take action by licensing the production of generic versions of the pill, which could enhance accessibility.
The implications of such a low-cost option could significantly impact at-risk populations, enhancing public health outcomes through improved accessibility.